Literature DB >> 1612127

Effect of an arginine-specific ADP-ribosyltransferase inhibitor on differentiation of embryonic chick skeletal muscle cells in culture.

S V Kharadia1, T W Huiatt, H Y Huang, J E Peterson, D J Graves.   

Abstract

Primary cultures of embryonic chick skeletal myogenic cells were used as an experimental model to examine the possible role of mono(ADP-ribosyl)ation reactions in myogenic differentiation. Initial studies demonstrated arginine-specific mono(ADP-ribosyl)transferase activity in the myogenic cell cultures. We then examined the effect of a novel inhibitor of cellular arginine-specific mono(ADP-ribosyl)transferases, meta-iodobenzylguanidine (MIBG), on differentiation of cultured embryonic chick skeletal myoblasts. MIBG reversibly inhibited both proliferation and differentiation of embryonic chick myoblasts grown in culture. Micromolar (15-60 microM) concentrations of MIBG blocked myoblast fusion, the differentiation-specific increase in creatine phosphokinase activity, and both DNA and protein accumulation in myogenic cell cultures. Meta-iodobenzylamine, an analog of MIBG missing the guanidine group, had no effect. Low concentrations of methylglyoxal bis-guanylhydrazone, a substrate for cholera toxin with a higher Km than MIBG, also had no effect, but higher concentrations reversibly inhibited fusion. These findings suggest a possible role for mono(ADP-ribosyl)ation reactions in myogenesis. In addition, the total arginine-specific mono(ADP-ribosyl)transferase activity increased with differentiation in the myogenic cell cultures, and this increase was also blocked by MIBG treatment. Because high levels of activity were found in the membrane fraction derived from later, myotube cultures, the membrane fraction from 96-h cultures was incubated with [32P]NAD+ and subjected to electrophoresis and autoradiography. Three proteins, migrating at 21, 20, and 17 kDa, that were ADP-ribosylated in the absence, but not the presence, of MIBG were identified. These proteins may be endogenous substrates for this enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612127     DOI: 10.1016/0014-4827(92)90345-9

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Molecular characterization of NAD:arginine ADP-ribosyltransferase from rabbit skeletal muscle.

Authors:  A Zolkiewska; M S Nightingale; J Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

2.  Inactivation of platelet-derived growth factor-BB following modification by ADP-ribosyltransferase.

Authors:  B A Saxty; M Yadollahi-Farsani; P D Upton; S R Johnstone; J MacDermot
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 3.  Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?

Authors:  Paul O Hassa; Sandra S Haenni; Michael Elser; Michael O Hottiger
Journal:  Microbiol Mol Biol Rev       Date:  2006-09       Impact factor: 11.056

Review 4.  Posttranslational modifications of desmin and their implication in biological processes and pathologies.

Authors:  Daniel L Winter; Denise Paulin; Mathias Mericskay; Zhenlin Li
Journal:  Histochem Cell Biol       Date:  2013-10-04       Impact factor: 4.304

Review 5.  Vertebrate mono-ADP-ribosyltransferases.

Authors:  A Zolkiewska; I J Okazaki; J Moss
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

6.  NAD-dependent inhibition of the NAD-glycohydrolase activity in A549 cells.

Authors:  Enrico Balducci; Luigi G Micossi
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.396

7.  ADP ribosylation of human neutrophil peptide-1 regulates its biological properties.

Authors:  Gregorino Paone; Akihiro Wada; Linda A Stevens; Abul Matin; Toshiya Hirayama; Rodney L Levine; Joel Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

8.  ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways.

Authors:  Ling Tan; Xiaodan Song; Xin Sun; Ning Wang; Ying Qu; Zhijun Sun
Journal:  Oncotarget       Date:  2016-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.